Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Gansu Maternal and Child Health Hospital | UNKNOWN |
| Hanzhong Central Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
The main objectives of this study are to construct a multi-omics-based prognostic and side-effect prediction model for cervical cancer based on pre-treatment imaging, digital pathology, genomics, proteomics, molecular biology, metabolomics, and intestinal flora characteristics data of cervical cancer patients, combined with patients' clinical information, to guide the precise treatment of cervical cancer patients; and to deeply excavate the characteristics related to recurrent cervical cancer based on time-series multi-omics data. Construct an artificial intelligence auxiliary model for dynamic monitoring of cervical cancer recurrence based on longitudinal multi-omics. To provide a real-time and timely tool for clinical early prediction, early identification, early diagnosis and early intervention of cervical cancer, to prolong the survival time and improve the quality of patients' survival.
1. Construct a prognosis and side effect prediction model based on pre-treatment multi-omics features of cervical cancer patients.
2.Mining recurrent tumor characteristics based on multi-omics data and constructing a comprehensive assessment model for recurrence risk .
3. Establish the prognosis and side-effect prediction and dynamic monitoring system of cervical cancer.
a. Docking the above constructed model with the outpatient system to construct a prognosis and side reaction prediction and dynamic monitoring system in the process of cervical cancer diagnosis and treatment; b. Constructing an intelligent decision support system through the prognosis and side reaction prediction and risk dynamic assessment model, implementing the application of recurrence prediction and dynamic monitoring system, and assisting the clinicians to make decisions on intervention measures.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| training group | The training group is used to train the model. |
| |
| validation group | The validation group is used to evaluate model performance. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Observational study | Other | Our study does not have any exposure factors. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Circulating Tumor Cell Count | Number of Circulating Tumor Cell Count (CTC count), cells/mL | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| Concentration of Alpha-fetoprotein (AFP) | Concentration of Alpha-fetoprotein (AFP), ng/mL | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| Concentration of Carcinoembryonic Antigen (CEA) | Concentration of Carcinoembryonic Antigen (CEA), ng/mL | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| Concentration of carbohydrate antigen 199 (CA199) | Concentration of carbohydrate antigen 199 (CA199), U/mL | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| Concentration of Squamous Epithelial Cell Carcinoma Antigen (SCC-Ag) | Concentration of Squamous Epithelial Cell Carcinoma Antigen (SCC-Ag), ng/mL | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| Concentration of carbohydrate antigen 125(CA125) | Concentration of carbohydrate antigen 125(CA125), U/mL. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Cervical cancer patients receiving radiotherapy
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jinlu Ma, Doctor | Contact | 18992842959 | majinlu@xjtufh.edu.cn | |
| Mengjiao Cai, Doctor | Contact | 15339267236 | 664642357@qq.com |
| Name | Affiliation | Role |
|---|---|---|
| Jinlu Ma | First Affiliated Hospital of Xian Jiaotong University | Study Chair |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002583 | Uterine Cervical Neoplasms |
| ID | Term |
|---|---|
| D014594 | Uterine Neoplasms |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
| ID | Term |
|---|---|
| D019370 | Observation |
| ID | Term |
|---|---|
| D008722 | Methods |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood, urine, feces, intestinal flora
| From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| Count of Bacteria in urine | Count of Bacteria in urine, colony-forming units (CFU)/mL. | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| Count of bacteria in stool | Count of bacteria in stool, colony-forming units (CFU)/mL | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| 5-year overall survival rate of Participants | the proportion of patients who are alive at least 5 years after their initial diagnosis of cancer, regardless of the cause of death,% | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| disease-free survival of Participants | the length of time from the start of treatment until either the recurrence of cancer or death from any cause, months | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| progression-free survival of Participants | the start of treatment until either the recurrence of cancer or death from any cause, months | From data of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. |
| D009369 |
| Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |